These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?AeroVironment, Inc. (NASDAQ:AVAV) decreased 19.45% this week after the US government issued a stop work order to AeroVironment on SCAR program.DraftKings Inc. (NASDAQ:DKNG) fell 14.4% this week. Sr. betting analyst Bill Speros posted on X that a judge allowed Massachusetts to block Kalshi from offering sports-related contracts in the state. He quoted the ruling saying the state can seek an injunction unless Kal ...

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - The investment group targets high-yield, dividend growth opportunities, offering portfolios with dividend yields up to 10% [2] - The service provides research on various investment vehicles including REITs, ETFs, closed-end funds, preferreds, and dividend champions [2] Group 2 - The investment approach is defensive in nature, aimed at medium- to long-term horizons [2] - The group emphasizes dependable monthly income for investors [2]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.I am Gen Alpha. I have more than 14 years of investment experience, and an MBA in Finance. I focus on stocks that are more defensive in nature, with a medium ...

Abbott logo on tablet beside Libre glucose sensor and BinaxNOW test kit in a clinical lab setting. Key Points Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone. Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss. A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case. Interested in ...

Core Viewpoint - Abbott Laboratories (ABT), known as a Dividend King, experienced a decline in stock price following a mixed Q4 earnings report, indicating resilience but also facing headwinds in certain segments [1] Financial Performance - The Q4 earnings report was mixed, suggesting that while the company shows resilience, there are negative impacts from challenges in some segments [1] Market Reaction - The stock price drop reflects investor sentiment in response to the earnings report, highlighting the market's reaction to the company's performance [1]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Score identifies attractive stocks using financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors seeking undervalued opportunities [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing metrics like weekly price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.9% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Stock to Watch: Abbott (ABT) - Abbott, rated 2 (Buy) on the Zacks Rank, has a VGM Score of B and a Value Style Score of B, with a forward P/E ratio of 19.16, indicating attractive valuation [11] - Recent upward revision of earnings estimates for fiscal 2026 has increased the Zacks Consensus Estimate to $5.67 per share, with an average earnings surprise of +0.7% [12]

Group 1 - Worldwide Nutrition sales decreased by 8.9% on a reported basis and 9.1% on an organic basis in the fourth quarter [1] - The results in the quarter were influenced by lower sales volumes compared to the prior year and new strategic price actions aimed at increasing future volume growth [1] - Abbott (ABT) anticipates boosting volume growth with the launch of several new products in 2026 [1]

Core Insights - Abbott Laboratories reported Q4 2025 sales of $11.46 billion, a 4.4% increase year-over-year, but fell short of analyst projections by approximately 3% [2] - Adjusted EPS for the quarter was $1.50, meeting expectations, while total annual adjusted EPS reached $5.15, indicating a 10% growth [2] Financial Performance - Organic sales growth decreased to 3% during the quarter due to reduced demand in some areas [4] - Adjusted gross margin increased by 20 basis points to 57.1%, and operating margin expanded by 150 basis points to 25.8%, reflecting effective cost management [4] - Guidance for 2026 projects organic sales growth of 6.5%-7.5% and an adjusted EPS around $5.68 at the midpoint, aligning with consensus expectations [6] Valuation Dynamics - Abbott is currently priced at around $109 per share, trading at 21 times its trailing adjusted EPS of $5.15, down from a three-year average P/E of 24 times [6][7] - The forward P/E based on guidance is 19 times, indicating potential stability, but slowdowns in Nutrition and uncertainties regarding acquisitions limit optimism [7] Segment Performance - Medical Devices segment showed strong demand, particularly in structural heart and neuromodulation, with Freestyle Libre contributing significantly to organic growth [10] - Diagnostics revenue is normalizing post-COVID, with the Exact Sciences acquisition valued at up to $23 billion expected to enhance this sector [10] - Nutrition sales declined due to market dynamics, raising concerns about future growth in this segment [10] Future Catalysts and Risks - Potential upside for Abbott depends on realizing synergies from Exact Sciences, stabilization in Nutrition, and successful execution in high-growth devices [8] - Downside risks include persistent weakness in Nutrition, regulatory challenges with the Exact Sciences acquisition, and overall caution in medtech spending [9]

Core Viewpoint - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey, aiming for financial independence through investments [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since around 2009 [1]. - The blog "Kody's Dividends" was launched in July 2018 to document the author's financial independence journey through dividend growth investing [1]. - The author credits the blog for introducing them to the Seeking Alpha community as an analyst [1].

Hi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend investing since about 2009.Since July 2018, I have ran Kody's Dividends. This is a blog that is documenting my journey towards financial independence using dividend growth investing as the means to transform the dream of financial independence into a reality. It's also th ...